Fact checked byMindy Valcarcel, MS

Read more

October 08, 2023
1 min read
Save

Radiation oncologist appointed to leadership role at NYU Langone’s Perlmutter Cancer Center

Fact checked byMindy Valcarcel, MS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Michael J. Zelefsky, MD, has been appointed director of brachytherapy for NYU Langone’s Perlmutter Cancer Center.

Zelefsky — recognized for his expertise in radiation oncology — also will serve as vice chair for academic and faculty affairs in NYU Grossman School of Medicine’s department of radiation oncology, as well as professor in the department of radiation oncology. He will lead the genitourinary cancer disease management group.

Infographic with headshot of Michael J. Zelefsky, MD

Zelefsky most recently served as chief of the brachytherapy service, vice chair of clinical research and director of genitourinary radiation oncology at Memorial Sloan Kettering Cancer Center.

“Dr. Zelefsky brings an unparalleled level of expertise and leadership that will further elevate our team at Perlmutter Cancer Center,” Alec Kimmelman, MD, PhD, Anita Steckler and Joseph Steckler chair of the department radiation oncology, said in a press release. “With his proven leadership ability, we are certain to develop new innovative treatment approaches, expand our research capabilities, and enhance our work as a comprehensive cancer center, delivering exceptional patient-centered care.”

Zelefsky has made multiple contributions to the field of prostate cancer, developing clinical practice guidelines and influencing treatment protocols worldwide. He helped develop intensity-modulated radiotherapy for the treatment of prostate cancer.

In his new role, he will work with Perlmutter Cancer Center’s urologic and medical oncology teams to develop a multidisciplinary approach toward diagnosis, treatment and management of adverse effects.

“I’m not simply continuing what I’ve been doing, but going to the next level at NYU Langone, and incorporating the expertise that can be found here,” Zelefsky said in the release. “We want to personalize the treatments for our patients, and best select the optimal therapy based on biologic and genetic markers, as well as quality-of-life variables.”